Kairos Pharma

Mike-new

Michael Keyoung

MD and Ph.D. in Neuroscience and Neurology from Cornell and Sloan Kettering (MSKCC), UCSF Health, Biomedical Fellow at Rockefeller and MSKCC

  • Senior ME for CBC Group, a healthcare-dedicated PE firm with over US$9 Billion AUM
  • 20+ year career as a physician, executive and institutional investor in US, Europe and Asia advising Eli Lilly, Bausch & Lomb, and Samsung Electronics/Biologicson Asian expansion, global drug development and commercial/partnership strategies
  • Former CEO of Genexine (KOSDAQ: 095700 w/ $1 Billion MC), led clinical development in Europe and Asia, raised $100M and created partnerships with Merck, Fosun Pharma, Tasly Pharma and Kalbe Pharma valued at over $250M
  • Former President of Catalyst Biosciences, (NASDAQ: CBIO) a clinical stage hemophilia and ophthalmology company partnered with Pfizer, MedImmuneand Isu Abxis
  • Previous Board Chair of AffaMed Therapeutics and Director of Graybug Vision and InxMed
  • Board member of Hugel Inc (kosdaq: 145020.KQ)